Breaking New Ground in Personalized Cancer Care

Solid IO is proud to announce its first scientific publication, a significant milestone in its mission to redefine cancer diagnostics. The research conducted in collaboration with the University of Helsinki, Helsinki University Hospital, and the iCAN Flagship, highlights how Solid IO’s tumor-on-chip platform delivers insights into immune responses to cancer therapies.

‍

‍Highlights From the Research

• Precision immunotherapy prediction
  The platform demonstrated the possibility to predict the effectiveness of immunotherapies like anti–PD-1 for individual patients, particularly those with non-small cell lung cancer (NSCLC).
• Discovering synergistic treatment combinations
  The study found a combination therapy of anti–PD-1 and Cbl-b inhibitors that successfully reactivated immune responses in patients resistant to standard treatments.
• Identifying novel biomarkers
  Researchers discovered new identifying biomarkers, including Cbl-b upregulation, providing actionable insights for more tailored and effective treatment strategies.

‍

“Our work showcases how patient-centric & fully human model systems patient-centric & fully human model systems can be harnessed to understand and overcome the barriers of immunotherapy resistance in cancer treatment,” said Dr. Heidi Haikala, CSO of Solid IO and the corresponding author of the study.

‍“This represents an important step toward a future where treatment decisions are guided by patient-specific biology.”

‍

‍Shaping the Future of Precision Oncology

‍Solid IO’s platform is a leap forward in personalized medicine, enabling the replication of patient-derived tumor microenvironment to analyze immune responses in real-time. This approach empowers hospitals, researchers, and pharmaceutical innovators to refine therapies with precision, reducing the time and cost of clinical development while improving patient outcomes.

‍“This study marks an important chapter for Solid IO, demonstrating how our tumor-on-chip technology can bridge the gap between research and real-world clinical application,” said Noora Hujala, CEO of Solid IO.

‍“We’re not just advancing science; we’re redefining how cancer care is delivered.”

‍

‍A Call for Collaboration

‍Solid IO is actively seeking partners - pharma, clinicians, and researchers - to join forces in pushing the boundaries of cancer diagnostics and immunotherapy. Together, we can accelerate innovation, improve access to life-saving therapies, and bring precision oncology to those who need it most.

‍

‍Read the Full Study

‍Dive deeper into this research and its impact on the future of oncology by reading the full study in Science Advances:

‍https://www.science.org/doi/10.1126/sciadv.adq6830